[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Su HH, Chu ST, Hou YY, Chang KP, Chen CJ: Spindle cell carcinoma of the oral cavity and oropharynx: factors affecting outcome. J Chin Med Assoc; 2006 Oct;69(10):478-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle cell carcinoma of the oral cavity and oropharynx: factors affecting outcome.
  • BACKGROUND: Spindle cell carcinoma (SpCC) is considered to be a rare variant of squamous cell carcinoma (SCC).
  • The aim of this study was to elucidate the treatment and outcome of oral and oropharyngeal SpCC.
  • METHODS: All the medical records of patients with the diagnosis of SpCC in the oral cavity and oropharynx in our hospital from 1994 to 2005 were reviewed.
  • The clinical features, treatments and survival of the patients were evaluated.
  • The median overall survival time was 8.89 months.
  • CONCLUSION: The behavior of SpCC seems to be more aggressive than that of SCC at a similar stage.
  • Seeking an effective chemotherapy protocol is important for the control of distant recurrence.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Mouth Neoplasms / surgery. Oropharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17098672.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


2. Ishii N, Yonese J, Tsukamoto T, Maezawa T, Fukui I, Ishikawa Y, Aoki N: [Multiple synchronous primary malignant tumors of fibrosarcoma and squamous cell carcinoma in the urinary bladder: a case report]. Nihon Hinyokika Gakkai Zasshi; 2002 Jul;93(5):642-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple synchronous primary malignant tumors of fibrosarcoma and squamous cell carcinoma in the urinary bladder: a case report].
  • A 65-year-old housewife presented with a diagnosis of malignant spindle cell tumor of the bladder which had been diagnosed by work up for chance hematuria.
  • Urine cytology revealed a small number of squamous epithelial cells showing dyskeratosis but no spindle cells.
  • Computed tomography and magnetic resonance images showed a markedly enhanced mass, 4 cm in diameter, on the anterior wall of the urinary bladder, which appeared to be adhesive to the pubic bone.
  • The tumor corresponded to a fibrosarcoma that infiltrated the adipose tissue surrounding the urinary bladder.
  • The entire mucosa of the bladder showed diffuse squamous metaplasia, and well differentiated squamous cell carcinoma with pearl formation was found in part.
  • These two malignant tumors were clearly apart from each other, resulting in the histologic diagnosis of synchronous multiple malignant tumors of the bladder.
  • The patient developed a local relapse and pulmonary metastasis of fibrosarcoma one month postoperatively and died two month later without any response to chemotherapy (CYVADIC) and radiotherapy.
  • The current case seems to be the first one in Japan (third in the world) of a patient with multiple synchronous primary malignant tumors, carcinoma and sarcoma, airsing in the urinary bladder.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Fibrosarcoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174642.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 12
  •  go-up   go-down


3. Beyer CF, Zhang N, Hernandez R, Vitale D, Lucas J, Nguyen T, Discafani C, Ayral-Kaloustian S, Gibbons JJ: TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res; 2008 Apr 1;68(7):2292-300

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Structurally, it is one of a class of compounds, triazolo[1,5a]pyrimidines, previously not known to bind to tubulin.
  • The morphologic character of the presumptive polymer is unknown at present.
  • When applied to cultured human tumor cells at concentrations near its IC(50) value for cytotoxicity (34 nmol/L), TTI-237 induced multiple spindle poles and multinuclear cells, as did paclitaxel, but not vincristine or colchicine.
  • In a cell line expressing a high level of P-glycoprotein, the IC(50) of TTI-237 increased 25-fold whereas those of paclitaxel and vincristine increased 806-fold and 925-fold, respectively.
  • TTI-237 was active in vivo in several nude mouse xenograft models of human cancer, including LoVo human colon carcinoma and U87-MG human glioblastoma, when dosed i.v. or p.o.
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / drug therapy. Cell Line, Tumor. Drug Screening Assays, Antitumor. Female. HeLa Cells. Humans. Mice. Mice, Nude. Microtubules / drug effects. Microtubules / metabolism. Tubulin / metabolism. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18381436.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hydrocarbons, Halogenated; 0 / Triazoles; 0 / Tubulin; P14M0DWS2J / cevipabulin
  •  go-up   go-down


Advertisement
4. Akiyama F, Horii R: Therapeutic strategies for breast cancer based on histological type. Breast Cancer; 2009;16(3):168-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic strategies for breast cancer based on histological type.
  • Breast cancer has various histological types that reflect not only morphological features but also biological characteristics.
  • Therefore, it is not an exaggeration to say that breast cancers of different histological types are different diseases.
  • It is generally accepted that the histological types of breast cancer are clinically significant because they serve as prognosticators and as the common language for improving the accuracy of clinical diagnosis.
  • It is necessary to diagnose breast cancer at the level of not only histological findings by needle biopsy, but also the histologic type based on diagnostic imaging and cytological diagnosis.
  • From the viewpoint of treatment, preoperative drug therapy is being performed more frequently to shrink tumors before breast-conserving therapy or to determine treatment sensitivity.
  • The prognosis is favorable for patients who respond completely or patients in whom interstitial infiltration is completely eliminated histopathologically, and, as a result, it is important to assess therapeutic efficacy clinically and pathologically.
  • Past experience has shed some light on differentiating cancers responsive to drug therapy from those unresponsive to drug therapy, as well as differentiating cancers in which therapeutic efficacy can be easily ascertained from those in which therapeutic efficacy cannot be easily ascertained.
  • Preoperative drug therapy can be planned by making a histological diagnosis based on needle biopsy findings.
  • Preoperative drug therapy is not indicated for noninvasive carcinoma and papillotubular carcinoma (invasive carcinoma with predominant intraductal components).
  • While complete loss of interstitial infiltration can be expected with solid-tubular carcinoma, it cannot be expected with other histological types, such as invasive lobular carcinoma, adenoid cystic carcinoma, or metaplastic carcinoma (squamous-cell carcinoma and spindle-cell carcinoma).
  • On therapeutic response assessment, the clinical and pathological findings generally match for solid-tubular carcinoma but not for scirrhous carcinoma and invasive lobular carcinoma.
  • With mucinous carcinoma, mucus accumulation can remain, even though most cancer cells disappear; as a result, assessment based on tumor diameter changes is difficult.
  • Histological diagnosis is also significant from the viewpoint of drug sensitivity, and it is important to maintain the accuracy of histological diagnosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma / drug therapy
  • [MeSH-minor] Female. Humans. Neoadjuvant Therapy. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19479319.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T: Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer; 2010 Apr;17(2):118-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Morphologically, the TN subtype was more frequently classified as solid-tubular carcinoma.
  • Mucinous, tubular, or secretary carcinomas were frequently found in the hormone receptor positive/HER2 negative subtype, while squamous cell carcinoma, spindle cell carcinoma, and metaplastic carcinoma with bone/cartilage metaplasia were very frequently found in the TN group.
  • Apocrine carcinoma was also found very frequently in the TN group.
  • Selection of chemotherapy was not based on receptor subtypes, but was determined by the degree of tumor progression.
  • CONCLUSIONS: Although TN types are similar to basal-like breast tumor, as determined by gene profiling, their diagnosis needs verification by determination of the level of epidermal growth factor receptor or cytokeratin 5/6 expression.
  • TN type should be examined further for immunohistochemical features and analyzed for prognostic details in this cohort.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Humans. Japan. Middle Aged. Prognosis. Receptor, ErbB-2 / metabolism. Registries. Societies, Medical / statistics & numerical data. Young Adult


6. Gotoh M, Yamamoto Y, Huang CL, Yokomise H: A combined small cell carcinoma of the lung containing three components: small cell, spindle cell and squamous cell carcinoma. Eur J Cardiothorac Surg; 2004 Nov;26(5):1047-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combined small cell carcinoma of the lung containing three components: small cell, spindle cell and squamous cell carcinoma.
  • A 61-year-old man was referred to our hospital because of rapid growth of a mass shadow revealed by chest radiography.
  • The mass was diagnosed as pure small cell carcinoma by CT-guided needle biopsy, and the patient underwent chemotherapy.
  • Postoperatively, the mass was diagnosed as small cell carcinoma combined with small cell, spindle cell and squamous cell carcinoma.
  • We report this case in view of the rarity of this combination of morphologic patterns in a primary bronchogenic carcinoma.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2005 Apr;27(4):734; author reply 735 [15784404.001]
  • (PMID = 15519208.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Tang PA, Siu LL, Chen EX, Hotte SJ, Chia S, Schwarz JK, Pond GR, Johnson C, Colevas AD, Synold TW, Vasist LS, Winquist E: Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs; 2008 Jun;26(3):257-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.
  • Ispinesib (SB-715992) inhibits the mitotic kinesin spindle protein (KSP), a novel target for anticancer therapy.
  • A phase II study was conducted to examine the efficacy of ispinesib in recurrent or metastatic head and neck squamous cell carcinoma (RMHNSC).
  • Patients with up to one prior line of chemotherapy for RMHNSC were treated with ispinesib 18 mg/m2 IV over 1 hour every 21 days.
  • Twenty-one patients were enrolled onto this study with a target stage I sample size of 19.
  • The median time to progression was 1.4 (95% CI 1.3-2.3) months, median survival was 3.5 (95% CI 2.8-7.8) months, and 1 year overall survival was 20% (95% CI 8.3-48.1%).
  • Archival tissues (n = 14) demonstrated low to moderate KSP expression by immunohistochemistry.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzamides / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Female. Gene Expression. Humans. Infusions, Intravenous. Kinesin / antagonists & inhibitors. Leukopenia / chemically induced. Male. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Recurrence, Local / drug therapy. Neutropenia / chemically induced. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1245-51 [1634913.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3276-80 [15126370.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):257-63 [1732427.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):18-23 [2416423.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3562-7 [15908667.001]
  • [Cites] Curr Opin Pharmacol. 2001 Aug;1(4):370-7 [11710735.001]
  • [Cites] Br J Cancer. 1990 Feb;61(2):311-5 [2178667.001]
  • [Cites] Science. 2000 Apr 7;288(5463):88-95 [10753125.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):521-6 [7522527.001]
  • [Cites] Lung Cancer. 2006 Nov;54(2):217-25 [16934364.001]
  • (PMID = 18038218.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM-62203
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / KIF11 protein, human; 0 / Quinazolines; BKT5F9C2NI / ispinesib; EC 3.6.4.4 / Kinesin
  •  go-up   go-down


8. Yoshimura Y, Mishima K, Obara S, Nariai Y, Yoshimura H, Mikami T: Treatment modalities for oral verrucous carcinomas and their outcomes: contribution of radiotherapy and chemotherapy. Int J Clin Oncol; 2001 Aug;6(4):192-200
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment modalities for oral verrucous carcinomas and their outcomes: contribution of radiotherapy and chemotherapy.
  • BACKGROUND: This clinical study focused, firstly, on the results of treatment and, secondly, on the anaplastic transformation, of oral verrucous carcinomas (OVCs) diagnosed and treated from 1981 to 1997 at the Department of Oral and Maxillofacial Surgery at Shimane Medical University Hospital.
  • METHODS: We analyzed the treatment modalities and outcomes for 15 patients with OVC.
  • RESULTS: Excluding the results for 4 palliatively treated patients, the disease-free survival rates of the patients after the initial treatments, were 82% at 5 years and 66% at 10 years; for all 15 patients, these rates were 57% and 46%, respectively.
  • Surgery alone and surgery combined with other treatments (such as radiotherapy and chemotherapy) appeared to yield disease-free survival rates to those achieved superior with other treatments whether single or combined; (78% vs 33% for 5-year disease-free survival; 52% vs 33% for 10-year disease-free survival); however, the difference was not significant (P = 0.47).
  • Well differentiated squamous cell carcinomas (W-SCCs) (n = 5) as well as spindle cell carcinoma (n = 1) were found in subsequent operative or biopsy specimens.
  • CONCLUSION: Surgery was the most reliable treatment method for OVC; however, radiotherapy combined with chemotherapy was the next most preferable treatment when surgery was not undertaken.
  • We also found that highly malignant transformation (anaplastic transformation) occasionally occurred during treatments for OVC.
  • [MeSH-major] Carcinoma, Verrucous / surgery. Mouth Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Male. Middle Aged. Palliative Care. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11706557.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Tonai K, Kitasato Y, Kawakami T, Kondo H, Koga T, Takata S, Katafuchi R, Kawasaki M: [Autopsy case of rapidly progressive pulmonary spindle cell carcinoma with multiple metastases to the brain and pancreas]. Nihon Kokyuki Gakkai Zasshi; 2009 Sep;47(9):828-32
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autopsy case of rapidly progressive pulmonary spindle cell carcinoma with multiple metastases to the brain and pancreas].
  • Chest X-ray and computed tomography showed a large mass lesion in the right lower lobe of the lung.
  • We diagnosed primary non-small cell lung cancer; cT3N1M1 stage IV.
  • Systemic chemotherapy using carboplatin and paclitaxcel was performed.
  • However, the treatment had no effect and he died two months after admission.
  • An autopsy showed pulmonary spindle cell carcinoma, with multiple metastases to the brain, pancreas, etc.
  • Pulmonary spindle cell carcinoma had been recognized as a variant of the squamous cell carcinoma for years, however, in the recent WHO and Japanese classification of lung tumors, it was redefined as an independent histological type.
  • We need to pay more attention to this type of lung cancer.
  • [MeSH-major] Autopsy. Brain Neoplasms / secondary. Carcinoma / secondary. Lung Neoplasms / pathology. Pancreatic Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827589.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Tanaka K, Mohri Y, Ohi M, Yokoe T, Koike Y, Morimoto Y, Miki C, Tonouchi H, Kusunoki M: Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol (R Coll Radiol); 2008 Oct;20(8):639-46
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy.
  • AIMS: HsMAD2 and BubR1 are crucial components of a functional mitotic checkpoint.
  • Recently, impaired mitotic checkpoints or decreased expression of mitotic checkpoint genes have been associated with sensitivity to certain anticancer drugs.
  • The current study aimed to evaluate the association of hsMAD2 and BubR1 with sensitivity to various anticancer drugs in oesophageal squamous cell carcinoma (ESCC) cell lines.
  • MATERIALS AND METHODS: HsMAD2 and BubR1 mRNA levels in six ESCC cell lines and 21 ESCC patients were determined by real-time reverse transcription polymerase chain reaction.
  • Responses to 5-fluorouracil, cisplatin, paclitaxel and docetaxel in human oesophageal cancer cell lines, TE1 and TE2, were evaluated by WST-8 colorimetric assay.
  • HsMAD2 and BubR1 were significantly higher in cancer tissue than in adjacent normal tissue (P < 0.01).
  • There was a significantly strong positive association between hsMAD2 and BubR1 in cancer tissue (P < 0.01).
  • Decreased hsMAD2 and BubR1 after radiochemotherapy may indicate the potential efficacy of taxanes as second-line chemotherapy for recurrent and metastatic oesophageal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Calcium-Binding Proteins / genetics. Carcinoma, Squamous Cell / genetics. Cell Cycle Proteins / genetics. Cisplatin / administration & dosage. Esophageal Neoplasms / genetics. Fluorouracil / administration & dosage. Protein-Serine-Threonine Kinases / genetics. Repressor Proteins / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Line, Tumor. Combined Modality Therapy. Female. Gene Expression. Humans. Mad2 Proteins. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691855.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Cell Cycle Proteins; 0 / MAD2L1 protein, human; 0 / Mad2 Proteins; 0 / Repressor Proteins; EC 2.7.11.1 / BUB1 protein, human; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Beatty JD, Atwood M, Tickman R, Reiner M: Metaplastic breast cancer: clinical significance. Am J Surg; 2006 May;191(5):657-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Metaplastic breast carcinoma (MBC) is a rare poorly differentiated breast cancer characterized by coexistence of ductal carcinoma with areas of matrix producing, spindle-cell, sarcomatous, or squamous differentiation; ER/PR/HER2 negativity; and a reputation for poor outcome.
  • METHODS: The Swedish Cancer Institute prospective breast cancer database (> 6500 patients; 1990-2005) has 24 MBC cases that were compared with typical breast cancer cases matched for age, date of diagnosis, stage, and ER/PR/HER2 status.
  • All patients had sentinel and/or axillary lymph node dissection and surgical resection; 18 received chemotherapy and 22 had radiation therapy.
  • Four patients had distant recurrences 5 to 88 months from diagnosis.
  • Comparison with matched typical breast cancer cases revealed no major significant difference in multidisciplinary treatment patterns, recurrence, or survival.
  • Increased, expression of EGFR (HER1) provides an opportunity for targeted tumor therapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Metastasis. Prospective Studies. Risk Factors. Survival Rate. Sweden / epidemiology


12. Boyle H, Fléchon A, Droz JP: [Uncommon bladder tumours]. Bull Cancer; 2010;97 Suppl Cancer de la vessie:51-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumeurs rares de la vessie.
  • Less than 500 of these cases are not transitional cell carcinoma, the most frequent pathological aspect.
  • Sarcomatoid, squamous and some adenocarcinomatous types are often pathological variants of the transitional pattern.
  • These tumours are possibly secondary to alkylating drug metabolites or pelvic radiotherapy and they have often a poor prognostic outcome.
  • This is also the case of spindle cell carcinoma, an endocrine variant of rare bladder cancers.
  • The treatment is generally based on an aggressive approach combining chemotherapy and a radical cystectomy.
  • The treatment is based on aggressive surgical exeresis of the tumour and surrounding structures.
  • The treatment is the same as this of lymphomas of other location and of the same histology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534390.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


13. Iwase H, Yamamoto Y, Kurebayashi J, Tsuda H, Ota T, Kurosumi M, Miyamoto K, Iwase T, Research Group of the Japanese Breast Cancer Society: Clinicopathologic and prognostic features of triple-negative breast cancer analyzed in registration data of the Japanese Breast Cancer Society, 11705 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e22122

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22122 Background: Triple-negative (TN) breast cancers which are negative for ER, PgR, and HER2 by immunohistochemistry are associated with a poor prognosis.
  • To clarify the characteristics of TN tumors, the data of the registration committee of the Japanese Breast Cancer Society were analyzed with respect to clinicopathologic factors, response to neoadjuvant chemotherapy (NAC) and prognosis.
  • In the 2,331 cases of all registered cases, the prognosis and details of the treatment were analyzed with 47.8 months as median follow-up period.
  • In 184 cases (7.9%), NAC was mainly performed using anthracycline and taxane based chemotherapy.
  • RESULTS: Luminal A type with positive for ER and/or PgR and negative for HER2 was most prevalent (53.8%), followed by TN type (15.5%).
  • TN cancers were diagnosed at a slightly advanced stage and more of the cases had lymph node metastases compared to other types.
  • Mucinous or tubular carcinoma was frequently seen in the Luminal A type.
  • Squamous cell, spindle cell carcinoma, or metaplastic carcinoma with bone/cartilage metaplasia was found in only TN type.
  • The HER2 type and TN type had statistically worse outcome compared to Luminal type in DFS and OS (P<.0001 and P<.0001, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963560.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Pan C, Yan M, Yao J, Xu J, Long Z, Huang H, Liu Q: Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells. Oral Oncol; 2008 Jul;44(7):639-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells.
  • Mitotic Aurora kinases are required for accurate chromosome segregation during cell division.
  • In the present study, we showed that Aurora kinase inhibitory small molecule VX-680 inhibited histone H3 phosphorylation at Ser10, a known in vivo substrate residue of Aurora kinase, in oral squamous cell carcinoma (OSCC) KB cells.
  • In addition, monopolar spindle structures, typical abnormalities induced by inhibition of Aur-A, were generated in VX-680-treated cells.
  • Inhibition of Aurora kinase led to reduced KB cell growth, as assessed by MTT assay.
  • In contrast, expression of cell survival factor Bcl-2 was reduced by VX-680 treatment in a dose-dependent manner.
  • Subsequently, nuclear characteristic of DNA fragmentation, indicative of apoptotic cell death, was clearly observed in these OSCC cells with Aurora kinase inhibitory VX-680.
  • Taken together, we showed that Aurora kinase inhibitory VX-680 led to apoptotic cell death in OSCC cells, suggesting a novel therapeutic target in oral cancer.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Piperazines / pharmacology. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Spindle Apparatus / drug effects
  • [MeSH-minor] Aneuploidy. Animals. Apoptosis / drug effects. Aurora Kinase A. Aurora Kinases. Blotting, Western. Caspase 3 / metabolism. Cattle. Cell Proliferation / drug effects. Fluorescent Antibody Technique, Indirect. Humans. Mice. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17996488.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Piperazines; 0 / Proto-Oncogene Proteins c-bcl-2; 639089-54-6 / VX680; EC 2.7.11.1 / Aurka protein, mouse; EC 2.7.11.1 / Aurora Kinase A; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


15. Orui H, Yamakawa M, Ishikawa A, Tsuchiya T, Ogino T: Malignant intramuscular forearm tumor with overwhelming squamous element. Pathol Int; 2000 Jul;50(7):574-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant intramuscular forearm tumor with overwhelming squamous element.
  • Squamous cell carcinoma (SCC) arising in the skeletal muscle is rare.
  • A case of a 19-year-old female patient with an intramuscular forearm tumor showing a histopathologically overwhelming squamous element is presented.
  • Microscopic examination revealed the classical features of SCC, including horn pearls, individual cell keratinization and intercellular bridge.
  • A malignant spindle cell component was not detected.
  • Neither evidence of another primary site nor skin lesion over the tumor was found and no metastatic lesion was detected in the 5 years since the appearance of the mass.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Muscle Neoplasms / pathology
  • [MeSH-minor] Actins / analysis. Actins / genetics. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Therapy, Combination. Female. Forearm / pathology. Humans. Lymph Node Excision. Lymph Nodes / surgery. Magnetic Resonance Imaging. Mitomycin / administration & dosage. Oncogene Proteins, Fusion / analysis. Oncogene Proteins, Fusion / genetics. Peplomycin / administration & dosage. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10886743.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Actins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SYT-SSX fusion protein; 50SG953SK6 / Mitomycin; 56H9L80NIZ / Peplomycin; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Hewes CA, Sullins KE: Use of cisplatin-containing biodegradable beads for treatment of cutaneous neoplasia in equidae: 59 cases (2000-2004). J Am Vet Med Assoc; 2006 Nov 15;229(10):1617-22
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of cisplatin-containing biodegradable beads for treatment of cutaneous neoplasia in equidae: 59 cases (2000-2004).
  • RESULTS: 22 tumors were sarcoids, 6 were fibrosarcomas, 1 was a fibroma, 2 were peripheral nerve sheath tumors, 11 were squamous cell carcinomas, 14 were melanomas (13 gray horses and 1 bay horse), 1 was a lymphosarcoma, 1 was an adenocarcinoma, and 1 was a basal cell tumor.
  • Forty of 48 (83%) animals for which long-term follow-up information was available were relapse free 2 years after treatment.
  • This included 20 of 22 animals with spindle cell tumors (including 11/13 horses with sarcoids), 6 of 10 animals with squamous cell carcinomas, 13 of 14 animals with melanomas, and 2 of 3 animals with other tumor types.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that implantation of cisplatin-containing biodegradable beads, with or without tumor debulking, may be an effective treatment for equidae with various cutaneous neoplasms.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Equidae. Horse Diseases / drug therapy. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / veterinary. Female. Horses. Laser Therapy / methods. Laser Therapy / veterinary. Male. Melanoma / drug therapy. Melanoma / surgery. Melanoma / veterinary. Retrospective Studies. Sarcoma / drug therapy. Sarcoma / surgery. Sarcoma / veterinary. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107319.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Bellino R, Arisio R, D'Addato F, Attini R, Durando A, Danese S, Bertone E, Grio R, Massobrio M: Metaplastic breast carcinoma: pathology and clinical outcome. Anticancer Res; 2003 Jan-Feb;23(1B):669-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metaplastic breast carcinoma: pathology and clinical outcome.
  • In this report we describe eleven cases of metaplastic breast carcinoma focusing on pathological features and the clinical behaviour of six patients with breast carcinoma with chondroid metaplasia (MCC).
  • Six cases showed chondroid metaplasia, three cases were spindle cell carcinoma and two were metaplastic squamous carcinoma.
  • The majority of patients (64%) had pT2 tumors without axillary node metastases: only two cases with spindle or squamous metaplasia showed nodal involvement.
  • Vascular invasion was observed in all squamous and spindle cell types and in 66% of MCC: estrogen and progesterone receptors were absent in 90% of the tumors.
  • Immunohistochemical staining for HER2/neu was detected in 72% of spindle cell and squamous carcinomas and in 33% of MCC.
  • Three cases staining highly for p53 were chondroid carcinomas: the staining was uniform both in carcinomatous and in sarcomatous tissue.
  • One patient with a chondroid metaplastic carcinoma was found to be a carrier of a BRCA1 mutation similar to the one responsible for sickle cell disease, possibly altering the spatial structure of the gene product.
  • Only six patients had follow-up periods longer than 36 months: five women were alive and disease-free: one patient with pT2N1 squamous metaplastic carcinoma died of disease 14 months after diagnosis.
  • Surgical and adjuvant treatment should follow the guidelines for the other most common breast cancers even if the need for chemotherapy is unknown due to the absence of large series randomized or observational data.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Follow-Up Studies. Humans. Immunohistochemistry. Metaplasia. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Receptor, ErbB-2 / biosynthesis. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis. Treatment Outcome. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12680165.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


18. Yura S, Terahata S, Ohga N, Yamashita T: A case of carcinosarcoma arising in the submandibular gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jun;103(6):820-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 54-year-old man presented with an 8-year history of a hard asymptomatic mass of the left submandibular area.
  • Total excision of the left submandibular gland with radical neck dissection was performed under a diagnosis of a submandibular tumor, probably a malignant mixed tumor.
  • The pathologic diagnosis was carcinosarcoma consisting of carcinomatous and sarcomatous elements.
  • The epithelial component was composed of squamous cell carcinoma, undifferentiated carcinoma, and adenocarcinoma.
  • The nonepithelial component was composed of chondrosarcoma, osteosarcoma, spindle cell sarcoma, rhabdomyosarcoma, and liposarcoma.
  • In view of the expected aggressive nature of the tumor, the patient was treated with postoperative radiotherapy of 60 Gy total, in 30 daily fractions of 2 Gy, and chemotherapy.
  • He currently remains well and free of disease 24 months after treatment.
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Care. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17531942.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement